Fig. 7: Administration of leucine (Leu) or chloroquine (CQ) increases cisplatin sensitivity in vivo. | Cell Death & Disease

Fig. 7: Administration of leucine (Leu) or chloroquine (CQ) increases cisplatin sensitivity in vivo.

From: BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism

Fig. 7

A Representative images of the xenograft tumors after the therapy (n = 5). Hela xenograft mice were treated with cisplatin, CQ, Leu, cisplatin plus CQ, or cisplatin plus Leu. B, C Tumor volume was measured and calculated every 3 days (n = 5). D, E The final tumor weight was measured (n = 5). F, G The bodyweight of mice was measured every 3 days (n = 5). H The protein expression levels of BCAT1, LC3B-I/II, mTOR, and phosphorylated mTOR were examined in the tumor tissues by Western blot. I IHC staining of Ki-67 and cleaved caspase-3 and TUNEL assay. The arrow represents a positive signal. Scale bars: 50 μm. (J) A schematic of the molecular mechanism. *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page